These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 34159305)

  • 21. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1.
    Zheng R; Fang X; Chen X; Huang Y; Xu G; He L; Li Y; Niu X; Yang L; Wang L; Li D; Geng H
    Clin Transl Med; 2020 Dec; 10(8):e261. PubMed ID: 33377632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic editing of hepatocyte genome in vivo.
    Ruiz de Galarreta M; Lujambio A
    J Hepatol; 2017 Oct; 67(4):818-828. PubMed ID: 28527665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of genome editing technologies to the study and treatment of hematological disease.
    Pellagatti A; Dolatshad H; Yip BH; Valletta S; Boultwood J
    Adv Biol Regul; 2016 Jan; 60():122-134. PubMed ID: 26433620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene Editing in Clinical Practice: Where are We?
    Mittal RD
    Indian J Clin Biochem; 2019 Jan; 34(1):19-25. PubMed ID: 30728669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders.
    Im W; Moon J; Kim M
    J Mov Disord; 2016 Sep; 9(3):136-43. PubMed ID: 27667185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Editing in Human Lymphoid Cells: Role for Donor DNA, Type of Genomic Nuclease and Cell Selection Method.
    Zotova A; Lopatukhina E; Filatov A; Khaitov M; Mazurov D
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29099045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TALEN-Mediated Homologous Recombination Produces Site-Directed DNA Base Change and Herbicide-Resistant Rice.
    Li T; Liu B; Chen CY; Yang B
    J Genet Genomics; 2016 May; 43(5):297-305. PubMed ID: 27180265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
    Chadwick AC; Wang X; Musunuru K
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9.
    LaFountaine JS; Fathe K; Smyth HD
    Int J Pharm; 2015 Oct; 494(1):180-94. PubMed ID: 26278489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
    Nishikido T; Ray KK
    Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A history of genome editing in mammals.
    Fernández A; Josa S; Montoliu L
    Mamm Genome; 2017 Aug; 28(7-8):237-246. PubMed ID: 28589393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exogenous gene integration mediated by genome editing technologies in zebrafish.
    Morita H; Taimatsu K; Yanagi K; Kawahara A
    Bioengineered; 2017 May; 8(3):287-295. PubMed ID: 28272984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Geminivirus-Mediated Genome Editing in Potato (Solanum tuberosum L.) Using Sequence-Specific Nucleases.
    Butler NM; Baltes NJ; Voytas DF; Douches DS
    Front Plant Sci; 2016; 7():1045. PubMed ID: 27493650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.
    Richards DY; Winn SR; Dudley S; Nygaard S; Mighell TL; Grompe M; Harding CO
    Mol Ther Methods Clin Dev; 2020 Jun; 17():234-245. PubMed ID: 31970201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani.
    Zhang WW; Matlashewski G
    mBio; 2015 Jul; 6(4):e00861. PubMed ID: 26199327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites.
    Jayavaradhan R; Pillis DM; Goodman M; Zhang F; Zhang Y; Andreassen PR; Malik P
    Nat Commun; 2019 Jun; 10(1):2866. PubMed ID: 31253785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases.
    Moscoso CG; Steer CJ
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32785089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future Challenges.
    Jiang L; Wang LY; Cheng XS
    J Atheroscler Thromb; 2018 Aug; 25(8):665-673. PubMed ID: 29899171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.